{"id":70723,"date":"2026-05-12T09:57:27","date_gmt":"2026-05-12T09:57:27","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70723"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"kisspeptin-10","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/kisspeptin-10\/","title":{"rendered":"Kisspeptina-10"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 Kisspeptina-10?<\/h3>\n<p style=\"margin: 0;\"><strong>Kisspeptina-10<\/strong> (KP-10) is a 10-amino-acid C-terminally amidated peptide and the most-studied active fragment of the KISS1 gene product. It is the apical endogenous regulator of GnRH neuronal activity \u2014 published studies established it as the upstream switch that initiates puberty and drives pulsatile gonadotropin release. Acts via the GPR54 (KISS1R) G-protein-coupled receptor. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">374675-21-5 (kisspeptina-10, humano)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>63<\/sub>H<sub>83<\/sub>N<sub>17<\/sub>O<sub>14<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1302.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH<sub>2<\/sub> (YNWNSFGLRF-NH<sub>2<\/sub>, 10 amino\u00e1cidos; fragmento ativo amidado na extremidade C-terminal do kisspeptina madura de 54 aa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco amarelado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (geladeira) para estoque de trabalho; \u221220 \u00b0C para armazenamento de longo prazo de frascos fechados. Reconstitu\u00eddo: 2\u20138 \u00b0C, usar em at\u00e9 ~30 dias. Proteger da luz. N\u00e3o congelar e descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de uso mais curtos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 Kisspeptina-10?<\/h2>\n<p><strong>Kisspeptina-10<\/strong> (KP-10) is a 10-amino-acid peptide and the most extensively studied active fragment of the KISS1 gene product, a 145-amino-acid preprokisspeptin that is processed into the 54-amino-acid mature kisspeptin and several shorter C-terminal active fragments (kisspeptin-14, kisspeptin-13, kisspeptin-10). All of the shorter fragments share the C-terminal 10-residue active core and have comparable potency at the kisspeptin receptor \u2014 kisspeptin-10 is the shortest fully active form and is by far the most common peptide in the kisspeptin literature. The well-characterised sequence is YNWNSFGLRF-NH<sub>2<\/sub>, peso molecular 1302.45 Da, f\u00f3rmula emp\u00edrica C<sub>63<\/sub>H<sub>83<\/sub>N<sub>17<\/sub>O<sub>14<\/sub>. A amida\u00e7\u00e3o na extremidade C-terminal \u00e9 essencial para a atividade completa do receptor. O KISS1 foi originalmente identificado como um gene supressor de met\u00e1stase por Lee et al. (Cancer Res 1996) e foi renomeado para kisspeptina em homenagem a Hershey, Pensilv\u00e2nia (lar dos chocolates Hershey\u2019s Kisses), onde o gene foi primeiro clonado. O papel reprodutivo \u2014 KISS1\/GPR54 como o regulador apical dos neur\u00f4nios GnRH e o guardi\u00e3o molecular da puberdade \u2014 foi estabelecido por dois artigos independentes em 2003 (Seminara et al., NEJM; de Roux et al., PNAS) demonstrando que muta\u00e7\u00f5es de perda de fun\u00e7\u00e3o no GPR54 causam hipogonadismo hipogonadotr\u00f3fico idiop\u00e1tico em humanos. A kisspeptina-10 \u00e9 fornecida como um p\u00f3 liofilizado de alta pureza para reconstitui\u00e7\u00e3o com \u00e1gua bacteriost\u00e1tica. Ela n\u00e3o \u00e9 <strong>n\u00e3o aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use, although ongoing IVF and infertility is investigating clinical applications. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Sinaliza\u00e7\u00e3o GPR54 \/ KISS1R e o Eixo HPG<\/h2>\n<p>What makes kisspeptin-10 mechanistically distinctive among reproductive-peptides is its position as the <strong>regulador apical a montante<\/strong> of the entire hypothalamic-pituitary-gonadal (HPG) axis. The peptide acts at a single receptor \u2014 GPR54 (also called KISS1R) \u2014 but the downstream cascade controls the full reproductive endocrine system in published studies:<\/p>\n<ul>\n<li><strong>Ativa\u00e7\u00e3o do GPR54 (KISS1R) nos neur\u00f4nios GnRH<\/strong> \u2014 A Kisspeptina-10 se liga ao GPR54, um receptor acoplado \u00e0 prote\u00edna G da classe A expresso densamente nos corpos celulares dos neur\u00f4nios GnRH nos n\u00facleos arqueados hipotal\u00e2micos e anteroventriculares periventriculares. A ativa\u00e7\u00e3o do receptor acopla-se \u00e0 G\u03b1<sub>q\/11<\/sub> e \u00e0 fosfolipase C, aumentando o c\u00e1lcio intracelular e desencadeando a despolariza\u00e7\u00e3o dos neur\u00f4nios GnRH e a libera\u00e7\u00e3o puls\u00e1til de GnRH no sistema porta hipofis\u00e1rio. Este \u00e9 o mecanismo mais direto \u2014 a descarga dos neur\u00f4nios GnRH \u00e9 o passo limitante da atividade do eixo HPG, e a kisspeptina \u00e9 o principal est\u00edmulo end\u00f3geno.<\/li>\n<li><strong>Regula\u00e7\u00e3o do eixo HPG em modo puls\u00e1til vs surto<\/strong> \u2014 Kisspeptin neurons in the arcuate nucleus drive the pulsatile GnRH\/LH pattern that maintains gonadal function throughout adult reproductive life. A separate population of kisspeptin neurons in the anteroventral periventricular nucleus (in rodents) generates the preovulatory LH surge in females. Studies using selective stimulation or knockout of these populations has dissected the two modes of HPG-axis output in published studies.<\/li>\n<li><strong>Inicia\u00e7\u00e3o da puberdade e o \u201cinterruptor da kisspeptina\u201d<\/strong> \u2014 Loss-of-function GPR54 mutations cause complete failure of puberty onset in humans and animal models; gain-of-function mutations cause central precocious puberty. The &#8220;kisspeptin switch&#8221; hypothesis \u2014 that puberty is initiated when arcuate kisspeptin neurons reach a critical activity threshold \u2014 is the dominant model of pubertal onset in current reproductive neuroscience studies.<\/li>\n<\/ul>\n<p>Kisspeptin-10 has a relatively short plasma half-life (~5\u201310 minutes) due to rapid proteolytic cleavage, particularly at the central RF amide motif by matrix metalloproteinases. Subcutaneous, intravenous, and intracerebroventricular routes are all documented in published studies; the central route is reserved for mechanism-of-action studies in rodents where the BBB-crossing question is relevant. For systemic HPG-axis studies, peripheral administration produces measurable GnRH\/LH responses within minutes of bolus injection. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Kisspeptin-10 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Endocrinologia reprodutiva e farmacologia do eixo HPG<\/strong> \u2014 din\u00e2mica puls\u00e1til de GnRH\/LH\/FSH, regula\u00e7\u00e3o por feedback gonadal, feedback de esteroides sexuais na atividade dos neur\u00f4nios de kisspeptina (Seminara et al., NEJM 2003; de Roux et al., PNAS 2003)<\/li>\n<li><strong>Puberty studies<\/strong> \u2014 tempo de in\u00edcio puberal em modelos de roedores, padr\u00f5es de ativa\u00e7\u00e3o de neur\u00f4nios de kisspeptina durante a transi\u00e7\u00e3o puberal, an\u00e1lise mecanicista da puberdade precoce central<\/li>\n<li><strong>Hypogonadotropic hypogonadism studies<\/strong> \u2014 preclinical models of GPR54 loss-of-function, kisspeptin-replacement protocols, mechanism-of-action studies for novel hypogonadism therapies<\/li>\n<li><strong>IVF and ovulation induction studies<\/strong> \u2014 alternatives to hCG trigger in IVF protocols, comparative LH-surge induction; clinical translation has reached Phase 2 in some studies programmes although kisspeptin-10 itself is not approved<\/li>\n<li><strong>Polycystic ovary syndrome (PCOS) studies<\/strong> \u2014 altered kisspeptin tone in PCOS preclinical models, LH-pulse frequency abnormalities, follicular maturation studies<\/li>\n<li><strong>Supress\u00e3o de met\u00e1stase e biologia do c\u00e2ncer<\/strong> \u2014 KISS1 was originally identified as a metastasis-suppressor gene; published studies continues to investigate kisspeptin&#8217;s anti-metastatic activity in breast, melanoma, and pancreatic cancer models<\/li>\n<li><strong>Cardiovascular and metabolic support<\/strong> \u2014 express\u00e3o emergente de KISS1R em cardiomi\u00f3citos e c\u00e9lulas \u03b2 pancre\u00e1ticas; efeitos na homeostase da glucose e contratilidade card\u00edaca em investiga\u00e7\u00e3o<\/li>\n<li><strong>Comparative reproductive peptide studies<\/strong> \u2014 compara\u00e7\u00e3o com <a href=\"https:\/\/medsbase.com\/pt-br\/pt-141\/\">PT-141 (Bremelanotide)<\/a> for melanocortin-axis sexual-behaviour studies and against <a href=\"https:\/\/medsbase.com\/pt-br\/oxytocin-acetate\/\">Acetato de Ocitocina<\/a> para pontos finais afiliativos e de liga\u00e7\u00e3o social.<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o kisspeptin-10 se encaixa no cen\u00e1rio de pept\u00eddeos reprodutivos e ativos no SNC, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/pt-141\/\">PT-141<\/a> (melanocortin agonist for sexual behaviour studies), <a href=\"https:\/\/medsbase.com\/pt-br\/oxytocin-acetate\/\">Acetato de Ocitocina<\/a> (neuropept\u00eddeo de comportamento afiliativo), e <a href=\"https:\/\/medsbase.com\/pt-br\/sermorelin\/\">Sermorelina<\/a> (GHRH-axis hypothalamic-pituitary studies). Browse the full <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">cat\u00e1logo de pept\u00eddeos<\/a> para compostos relacionados. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Kisspeptin-10 in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, HPG-axis pulse protocols, single-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo estendido, estudos de m\u00faltiplas coortes, menor custo por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. Because kisspeptin-10 dose ranges are in the low-microgram regime per administration, a single 5\u00a0mg vial supports many weeks of pulse-protocol use at typical doses. <\/p>\n<h2>Como Comparar \u2014 Kisspeptin-10 vs PT-141<\/h2>\n<p>Kisspeptin-10 e <a href=\"https:\/\/medsbase.com\/pt-br\/pt-141\/\">PT-141 (Bremelanotide)<\/a> are both small CNS-active peptides used in reproductive- and sexual-behaviour studies, but they act on fundamentally different pathways. Kisspeptin-10 acts on the endocrine HPG axis at the GnRH-neuron level; PT-141 acts on the melanocortin behavioural-sexual axis at the MC4R level. The two are mechanistically complementary rather than competing in study models. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kisspeptina-10<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">PT-141 (Bremelanotide)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 amino\u00e1cidos (decapept\u00eddeo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">7 amino\u00e1cidos (heptapept\u00eddeo c\u00edclico)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptor prim\u00e1rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GPR54 \/ KISS1R<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">MC3R \/ MC4R receptores de melanocortina<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito prim\u00e1rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Libera\u00e7\u00e3o de GnRH\/LH\/FSH (end\u00f3crino)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Comportamento sexual mediado pelo SNC (comportamental)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Studies domain<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eixo HPG, puberdade, hipogonadismo, FIV<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Desejo sexual, excita\u00e7\u00e3o, fun\u00e7\u00e3o er\u00e9til<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~5\u201310 min<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 horas (SC)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uso cl\u00ednico aprovado<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">None (Phase 2 in IVF studies)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FDA-approved as Vyleesi for HSDD (different molecule from pharmaceutical-grade)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013200 mcg, bolus ou pulso<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,25\u20132 mg, administra\u00e7\u00e3o \u00fanica<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The two peptides address different layers of reproductive biology \u2014 kisspeptin-10 the endocrine HPG axis, PT-141 the CNS-mediated behavioural axis \u2014 so they are not direct alternatives. Studies interested in pulsatile GnRH\/LH dynamics, puberty timing, or hypogonadism uses kisspeptin-10. Studies interested in CNS-mediated sexual-arousal pathways uses PT-141. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo n\u00e3o aberto, congele a \u221220 \u00b0C. A kisspeptina-10 liofilizada \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220 \u00b0C por at\u00e9 36 meses. Evite ciclos de congelamento-descongelamento no p\u00f3 liofilizado. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers a 100\u00a0mcg dose. For lower-dose work, further dilution into bacteriostatic water (with optional BSA carrier protein at 0.1%) can be used. Swirl gently \u2014 do <strong>n\u00e3o<\/strong> sacuda \u2014 e aguarde 2\u20135 minutos para dissolu\u00e7\u00e3o completa. Uma solu\u00e7\u00e3o reconstitu\u00edda corretamente deve estar l\u00edmpida e incolor. <strong>Ap\u00f3s a reconstitui\u00e7\u00e3o:<\/strong> armazene refrigerado a 2\u20138 \u00b0C e use dentro de 30 dias para estabilidade ideal. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento-descongelamento degradam a integridade do pept\u00eddeo. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. A kisspeptina-10 \u00e9 suscet\u00edvel \u00e0 clivagem proteol\u00edtica no motivo RF-amida C-terminal; a solu\u00e7\u00e3o reconstitu\u00edda deve ser usada prontamente dentro da janela de 30 dias para protocolos que exigem calibra\u00e7\u00e3o rigorosa de dose-resposta. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is Kisspeptin-10 used for in studies?<\/h3>\n<p>Kisspeptin-10 is used in studies investigating the hypothalamic-pituitary-gonadal (HPG) axis, GnRH neuron activity, pulsatile gonadotropin release, puberty onset, hypogonadotropic hypogonadism, polycystic ovary syndrome (PCOS), IVF and ovulation-induction alternatives to hCG, cancer metastasis suppression (KISS1 was originally identified as a metastasis-suppressor gene), and emerging cardiometabolic kisspeptin signalling. It is the canonical tool for KISS1R \/ GPR54 pharmacology. The pharmaceutical-grade kisspeptin-10 sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Como a Kisspeptina-10 \u00e9 diferente do PT-141?<\/h3>\n<p>Both are small CNS-active reproductive peptides, but they target different receptors and biological layers. Kisspeptin-10 acts on the GPR54\/KISS1R receptor on GnRH neurons and drives the endocrine HPG axis (LH, FSH, gonadal steroid production). PT-141 acts on MC3R\/MC4R melanocortin receptors in the CNS and drives behavioural-sexual responses (desire, arousal, erectile function). The two are mechanistically complementary and address different studies questions. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre Kisspeptina-10 e Kisspeptina-54?<\/h3>\n<p>Both are active fragments of the KISS1 gene product. Kisspeptin-54 (also called metastin) is the full-length mature 54-amino-acid peptide secreted in vivo. Kisspeptin-10 is the C-terminal 10-amino-acid active core, which retains essentially full receptor potency and is the most commonly used peptide because its smaller size makes synthesis cheaper, purity easier to verify, and reconstitution simpler. Kisspeptin-13 and kisspeptin-14 are intermediate cleavage products that also share the active C-terminal core. All four have comparable potency at GPR54. <\/p>\n<h3>What is the typical Kisspeptin-10 dose?<\/h3>\n<p>Published preclinical protocols typically use 10\u2013200\u00a0mcg per administration in rodent models, given subcutaneously or intravenously for bolus-pulse studies, or as continuous infusion for chronic-stimulation studies. Human IVF has used 6.4\u201312.8\u00a0\u03bcg\/kg as a single subcutaneous trigger dose. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg. <\/p>\n<h3>O Kisspeptin-10 \u00e9 aprovado pela FDA?<\/h3>\n<p>No. Kisspeptin-10 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 2 clinical studies in IVF ovulation induction is ongoing, but kisspeptin-10 has not been approved for any clinical indication. <\/p>\n<h3>Como o Kisspeptin-10 deve ser armazenado?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para estoque de trabalho de curto prazo, ou \u221220 \u00b0C para armazenamento de longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, usar dentro de 30 dias. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento-descongelamento degradam o pept\u00eddeo. Proteja da luz direta em todos os momentos. Para dilui\u00e7\u00f5es de trabalho de baixa concentra\u00e7\u00e3o, recomenda-se prote\u00edna carreadora BSA (0,1%) para minimizar perdas por adsor\u00e7\u00e3o. <\/p>\n<h3>Como reconstituir o Kisspeptin-10?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o liofilizado), agite suavemente e aguarde 2\u20135 minutos para dissolu\u00e7\u00e3o completa. N\u00e3o <strong>n\u00e3o<\/strong> Agite o frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 clara e incolor. Para um frasco de 5 mg + 2,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 2,5 mg\/mL. <\/p>\n<h3>Quais dosagens a MedsBase oferece?<\/h3>\n<p>MedsBase carries Kisspeptin-10 in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Por que o KISS1 foi originalmente chamado de kisspeptina?<\/h3>\n<p>O gene KISS1 foi descoberto como um gene supressor de met\u00e1stase por Lee et al. em Hershey, Pensilv\u00e2nia (Cancer Res 1996). O nome \u201ckisspeptina\u201d foi uma refer\u00eancia bem-humorada aos Hershey\u2019s Kisses, o chocolate ic\u00f4nico produzido na mesma cidade. O papel reprodutivo s\u00f3 foi caracterizado em 2003, com a publica\u00e7\u00e3o simult\u00e2nea de estudos sobre hipogonadismo por muta\u00e7\u00e3o no GPR54 humano no NEJM (Seminara et al.) e no PNAS (de Roux et al.). O pept\u00eddeo tem, portanto, a distin\u00e7\u00e3o incomum de ter sido caracterizado independentemente como um supressor de met\u00e1stase de c\u00e2ncer e o regulador apical da puberdade \u2014 dois pap\u00e9is que permanecem mecanicamente desconectados. <\/p>\n<h3>Does Kisspeptin-10 cause side reported effects?<\/h3>\n<p>Published preclinical and Phase 1\/2 clinical studies has documented good tolerability at typical doses. The predominant on-target effects are HPG-axis activation \u2014 rising LH, FSH, testosterone (males) or estradiol (females), and downstream gonadal steroid effects. Off-target findings include modest cardiovascular effects mediated by KISS1R expression on vascular tissue, and a flushing\/vasodilation effect noted in some human studies at higher doses. Long-term safety data outside contexts is limited. <\/p>\n<h3>Qual \u00e9 a meia-vida do Kisspeptin-10?<\/h3>\n<p>In preclinical and clinical studies, kisspeptin-10 has a plasma half-life of approximately 5\u201310 minutes following intravenous or subcutaneous administration. The short half-life is due to rapid proteolytic cleavage by matrix metalloproteinases at the central RF-amide motif. For chronic-stimulation studies, continuous infusion or repeated pulse-dosing protocols are used to maintain receptor occupancy. <\/p>\n<h3>How long does Kisspeptin-10 take to show effects in preclinical studies?<\/h3>\n<p>Acute LH responses to bolus kisspeptin-10 administration are detectable within 5\u201315 minutes in rodent and human studies. FSH and downstream gonadal steroid responses develop over hours to days. Chronic-stimulation effects on puberty timing in young rodent models manifest over the natural pubertal window \u2014 days to weeks depending on species and developmental stage at intervention. <\/p>\n<h3>Posso encomendar Kisspeptin-10 para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Kisspeptin-10 para todo o mundo atrav\u00e9s da nossa rede dedicada de envio de pept\u00eddeos. Pedidos exclusivos de pept\u00eddeos qualificam-se para o nosso servi\u00e7o de envio independente de pept\u00eddeos. Todas as encomendas s\u00e3o enviadas em embalagens com controle de temperatura, com rastreamento completo e cobertas pela nossa <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Reenvio Garantido<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Reproductive, CNS, and Behavioural Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Cyclic heptapeptide melanocortin agonist \u2014 CNS-mediated sexual-behaviour studies<\/li>\n<li><a href=\"\/pt-br\/oxytocin-acetate\/\"><strong>Acetato de Ocitocina<\/strong><\/a> \u2014 9-aa cyclic neuropeptide \u2014 social-bonding and affiliative behavioural support<\/li>\n<li><a href=\"\/pt-br\/sermorelin\/\"><strong>Sermorelina<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 hypothalamic-pituitary-axis studies<\/li>\n<li><a href=\"\/pt-br\/cjc-1295-with-dac\/\"><strong>CJC-1295 com DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth-axis studies<\/li>\n<li><a href=\"\/pt-br\/selank\/\"><strong>Selank<\/strong><\/a> \u2014 Anxiolytic heptapeptide \u2014 GABA \/ BDNF stress resilience<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore reproductive and CNS-active peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Navegue pela categoria completa <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\"><strong>cat\u00e1logo de pept\u00eddeos<\/strong><\/a>, com compostos relacionados incluindo <a href=\"https:\/\/medsbase.com\/pt-br\/pt-141\/\">PT-141 (Bremelanotide)<\/a> for melanocortin sexual-behaviour studies, <a href=\"https:\/\/medsbase.com\/pt-br\/oxytocin-acetate\/\">Acetato de Ocitocina<\/a> for affiliative-behaviour studies, and <a href=\"https:\/\/medsbase.com\/pt-br\/sermorelin\/\">Sermorelina<\/a> for hypothalamic-pituitary-axis studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Regulador apical da atividade neuronal de GnRH<br \/>\n\u2705 Agonista do receptor KISS1R\/GPR54<br \/>\n\u2705 HPG-axis &amp; puberty compound<br \/>\n\u2705 IVF and ovulation-induction studies<br \/>\n\u2705 Originalmente identificado como supressor de met\u00e1stase<\/p>\n<p><strong>Kisspeptina-10<\/strong> cont\u00e9m composto de pept\u00eddeo sint\u00e9tico.<\/p>","protected":false},"featured_media":70963,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6277,5441],"class_list":["post-70723","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-kisspeptin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/70723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=70723"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/70963"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=70723"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=70723"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=70723"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=70723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}